Pre-Made Lepunafusp Alfa Biosimilar, Fusion Protein targeting TFRC fused with human IDUA (iduronidase, alpha-L-) isoform 1 via a peptidyl linker: Recombinant therapeutic protein targeting CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90 for drug discovery and mechanism of action (MOA) research

Pre-Made Lepunafusp Alfa Biosimilar, Fusion Protein targeting TFRC fused with human IDUA (iduronidase, alpha-L-) isoform 1 via a peptidyl linker: Recombinant therapeutic protein targeting CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lepunafusp alfa is a blood-brain-barrier-penetrating form of recombinant human alpha-L-iduronidase fused to the alpha-L-iduronidase anti-transferrin receptor antibody Fab as pabinafusp alfa. Human alpha-L-iduronidase deficiency causes lysosomal storage disease mucopolysaccharidosis type I which leads to disrupted glycosaminoglycan catabolism.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-888-1mg	1mg	3090
GMP-Bios-INN-888-10mg	10mg	Inquiry
GMP-Bios-INN-888-100mg	100mg	Inquiry
GMP-Bios-INN-888-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lepunafusp Alfa Biosimilar, Fusion Protein targeting TFRC fused with human IDUA (iduronidase, alpha-L-) isoform 1 via a peptidyl linker: Recombinant therapeutic protein targeting CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90
INN Name	Lepunafusp Alfa
Target	TFRC
Format	Fusion Protein
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	F(ab')2 - G1 - kappa
VD LC	F(ab')2 - G1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	JCR Pharmaceuticals Co., Ltd (Ashiya Japan)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0